3,5-dinitro-2-dimethyldithiocarbamoylbenzonitrile | 959354-76-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-dinitro-2-dimethyldithiocarbamoylbenzonitrile
• 英文别名: 2-cyano-N,N-bis(methylsulfanyl)-4,6-dinitro-benzenecarbothioamide；2-cyano-N,N-bis(methylsulfanyl)-4,6-dinitrobenzenecarbothioamide
• CAS: 959354-76-8
• 化学式: C₁₀H₈N₄O₄S₃
• 分子量: 344.396
• InChiKey: VSHPRAQTRXTYCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  201
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  active charcoal 、 2-氯-3,5-二硝基苯甲腈 、 sodium N,N-dimethyldithiocarbamate dihydrate 生成 3,5-dinitro-2-dimethyldithiocarbamoylbenzonitrile
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Dithiocarbamate derivatives and their use as antibacterial agents
  申请人：MEDAC GmbH

  公开号：EP1312607A1

  公开（公告）日：2003-05-21

  Compounds of the formula I wherein X is a bivalent residue selected from the group consisting of have excellent antibacterial activities and are useful agents for the therapeutic or prophylactic treatment of infectious diseases in mammals (humans and animals) caused by bacteria, especially diseases like tuberculosis (TB) and lepra caused by mycobacteria and infectious diseases caused by staphylococci.

  式I的化合物，其中X是从所述群组中选择的二价残基，具有出色的抗菌活性，并且是治疗或预防哺乳动物（人类和动物）由细菌引起的传染病的有用药剂，特别是由分枝杆菌引起的肺结核（TB）和麻风病以及由葡萄球菌引起的传染病。
• DITHIOCARBAMATE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS
  申请人：MedacGesellschaft für klinischeSpezialpräparate mbH

  公开号：EP1448533A1

  公开（公告）日：2004-08-25
• [EN] DITHIOCARBAMATE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS<br/>[FR] DERIVES DE DITHIOCARBAMATE, ET LEUR UTILISATION COMME AGENTS ANTIBACTERIENS
  申请人：MEDAC KLINISCHE SPEZIALPRAEP

  公开号：WO2003042186A1

  公开（公告）日：2003-05-22

  The invention relates to the use of dithiocarbamate derivatives for the therapeutic or prophylactic treatment of infectious diseases in mammals (humans and animals) caused by bacteria, especially diseases like tuberculosis (TB) and lepra caused by mycobacteria and infectious diseases caused by staphylococci. The invention further relates to novel dithiocarbamate derivatives of the formula (I), wherein X is a bivalent residue selected from the group consisting of formulae (1, 2, 3, 4) having excellent antibacterial activities, and to pharmaceutical preparations containing the same.